<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id><journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id><journal-id journal-id-type="pmc">nar</journal-id><journal-id journal-id-type="publisher-id">Nucleic Acids Research</journal-id><journal-title-group><journal-title>Nucleic Acids Research</journal-title></journal-title-group><issn pub-type="ppub">0305-1048</issn><issn pub-type="epub">1362-4962</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17517774</article-id><article-id pub-id-type="pmc">PMC1920256</article-id><article-id pub-id-type="doi">10.1093/nar/gkm315</article-id><article-categories><subj-group subj-group-type="heading"><subject>Molecular Biology</subject></subj-group></article-categories><title-group><article-title>Disparate contributions of the Fanconi anemia pathway and homologous recombination in preventing spontaneous mutagenesis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hinz</surname><given-names>John M.</given-names></name><xref ref-type="corresp" rid="COR1">*</xref></contrib><contrib contrib-type="author"><name><surname>Nham</surname><given-names>Peter B.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Urbin</surname><given-names>Salustra S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Irene M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Thompson</surname><given-names>Larry H.</given-names></name></contrib></contrib-group><aff>Chemistry, Materials, &#x00026; Life Sciences Directorate, L441, Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, CA 94551-0808, USA</aff><author-notes><corresp id="COR1">*To whom correspondence should be addressed. <phone>+1 925 424 3686</phone><fax>+1 925 422 2099</fax><email>hinz4@llnl.gov</email></corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2007</year></pub-date><pub-date pub-type="epub"><day>21</day><month>5</month><year>2007</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>5</month><year>2007</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>35</volume><issue>11</issue><fpage>3733</fpage><lpage>3740</lpage><history><date date-type="received"><day>27</day><month>2</month><year>2007</year></date><date date-type="rev-recd"><day>11</day><month>4</month><year>2007</year></date><date date-type="accepted"><day>12</day><month>4</month><year>2007</year></date></history><permissions><copyright-statement>&#x000a9; 2007 The Author(s)</copyright-statement><copyright-year>2007</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/">http://creativecommons.org/licenses/by-nc/2.0/uk/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Fanconi anemia (FA) is a chromosomal instability disorder in which DNA-damage processing defects are reported for translesion synthesis (TLS), non-homologous end joining (NHEJ) and homologous recombination (HR; both increased and decreased). To reconcile these diverse findings, we compared spontaneous mutagenesis in FA and HR mutants of hamster CHO cells. In the <italic>fancg</italic> mutant we find a reduced mutation rate accompanied by an increased proportion of deletions within the <italic>hprt</italic> gene. Moreover, in <italic>fancg</italic> cells gene amplification at the <italic>CAD</italic> and <italic>dhfr</italic> loci is elevated, another manifestation of inappropriate processing of damage during DNA replication. In contrast, the <italic>rad51d</italic> HR mutant has a greatly elevated rate of <italic>hprt</italic> mutations, &#x0003e;85% of which are deletions. Our analysis supports the concept that HR faithfully restores broken replication forks, whereas the FA pathway acts more globally to ensure chromosome stability by promoting efficient end joining of replication-derived breaks, as well as TLS and HR.</p></abstract></article-meta></front><body><sec><title>INTRODUCTION</title><p>Fanconi anemia (FA) is a genetic disease characterized by diverse congenital abnormalities, early predisposition to cancer and progressive bone marrow failure due to defective hematopoiesis (<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>). Patients have mutations in one of at least 12 genes: <italic>FANCA, B, C, D1</italic> (also known as <italic>BRCA2</italic>), <italic>D2, E, F, G, I, J</italic> (<italic>BRIP1/BACH1</italic>), <italic>L, M</italic> (<italic>Hef</italic>), and <italic>N</italic> (<italic>PALB2</italic>). Many of the FANC proteins (FANCA/B/C/E/F/G/L/M/FAAP24/FAAP100) form a nuclear &#x02018;core complex&#x02019; (<xref ref-type="bibr" rid="B3 B4 B5 B6 B7">3&#x02013;7</xref>), the integrity of which is essential for the monoubiquitination of FANCD2 in response to DNA damage, including that from mitomycin C crosslinking or oxidative lesions from ionizing radiation (IR). During the cell cycle, monoubiquitinated FANCD2 appears during S phase and co-localizes at sites of putative double-strand breaks (DSBs) with nuclear foci of BRCA1 and Rad51(<xref ref-type="bibr" rid="B8">8</xref>), two key proteins in the DSB repair pathway of homologous recombination repair (HRR). HRR uses the sister chromatid, when it is available, as a template for error-free repair of DSBs caused by insults such as ionizing radiation, as well as for restarting broken replication forks during DNA synthesis (<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>). These processes are facilitated by the Rad51 recombinase, which requires mediator proteins including BRCA2 and five Rad51 paralogs (XRCC2, XRCC3, RAD51B, RAD51C, RAD51D) (<xref ref-type="bibr" rid="B11">11</xref>). The identification of FANCD1 as BRCA2 (<xref ref-type="bibr" rid="B12">12</xref>), and the physical associations between other FANC and HRR proteins such as XRCC3 (<xref ref-type="bibr" rid="B13">13</xref>), also suggest a role for the FANC &#x02018;pathway&#x02019; in preventing or repairing broken replication forks, and highlight a potential link between the FA proteins and the better defined HRR pathway.</p><p>Cells from FA patients typically show increased spontaneous chromatid breaks and gaps (<xref ref-type="bibr" rid="B14">14</xref>), and consistently show high sensitivity for cell killing and chromosomal aberrations in response to DNA crosslinking agents (<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B15">15</xref>). Treatment of FA cells with low doses of mitomycin C produces excessive chromosomal interchanges due to misrepair of chromatid breaks (<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>) (arising in S or G2 phases) by an end-joining repair pathway, such as DNA-PK-dependent (<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>) or PARP1-dependent (<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>) non-homologous end joining (NHEJ). Such cellular phenotypes are reminiscent of cells defective in HRR, including the well-studied rodent cell lines deficient in the Rad51 paralogs (<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>), which show high levels of spontaneous chromosomal aberrations and high sensitivity to crosslinking agents, suggesting an overlapping role for the FANC and HRR proteins in maintaining genome integrity. HRR capacity in FA cells, as indicated by synthetic reporter genes, is reported to be decreased (<xref ref-type="bibr" rid="B24 B25 B26">24&#x02013;26</xref>), increased (<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>) or unaltered (<xref ref-type="bibr" rid="B29">29</xref>). These approaches have not helped assess the functional overlap between the FA and HRR pathways.</p><p>The role of the FA pathway in DSB repair through DNA end joining mechanisms also has not been established. FA cells generally do not exhibit phenotypes associated with gross NHEJ deficiency, such as high IR sensitivity. It is not understood why various NHEJ assays in FA cells provide conflicting results. For example, studies based on chromosomally integrated reporter constructs containing a I&#x02013;Sce-I restriction site and PCR analysis found no reduction in NHEJ activity in FA cells from three complementation groups (A, D2 and G) compared to gene-complemented control cells (<xref ref-type="bibr" rid="B26">26</xref>). However, an intact FA pathway was required for the end-joining repair of DSBs in plasmid-based assays (both <italic>in vitro</italic> and <italic>in vivo</italic>) and for survival of cells after electroporation with restriction enzymes was reported (<xref ref-type="bibr" rid="B30 B31 B32">30&#x02013;32</xref>).</p><p>Although chromosomal rearrangements such as those associated with FA and HRR deficiencies are known to play a role in carcinogenesis, single-gene mutation and amplification, are not well characterized in FA and HHR mutant cells. Using an isogenic CHO <italic>rad51d</italic> knockout mutant, we recently showed that HRR deficiency causes a substantial increase (&#x0223c;12-fold) in the rate of spontaneous mutagenesis in the X-linked <italic>hprt</italic> (hypoxanthine phosphoribosyltransferase) gene, and in the rate of amplification at two loci (<italic>dhfr</italic>, &#x0223c;10-fold; <italic>CAD</italic>, &#x0223c;4-fold) (<xref ref-type="bibr" rid="B23">23</xref>). This mutant phenotype suggests a major role for HRR in rescuing broken DNA replication forks (<xref ref-type="bibr" rid="B23">23</xref>). Mutagenesis studies in human FA cells have given seemingly conflicting results (<xref ref-type="bibr" rid="B33">33</xref>). FA lymphoblasts had a &#x02018;reduced&#x02019; rate of mutagenesis in the <italic>hprt</italic> gene in response to treatments with monofunctional and bifunctional psoralens, whereas the spontaneous mutant frequencies were markedly &#x02018;increased&#x02019; in FA patients at two autosomal loci: glycophorin A (<italic>GPA</italic>) in erythrocytes (<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref>) and <italic>PIG-A</italic> in lymphoblasts (<xref ref-type="bibr" rid="B36">36</xref>). In chicken DT40 cells a requirement for a FANC protein (FANCC) to promote translesion synthesis (TLS) during crosslink repair was reported (<xref ref-type="bibr" rid="B37">37</xref>). Thus, the precise role of the FA proteins in mutagenesis remains unclear, and may indeed involve multiple cellular mechanisms of maintaining genomic integrity.</p><p>In this study, we use a model mutagenesis system of isogenic CHO <italic>fancg</italic> (<xref ref-type="bibr" rid="B38">38</xref>) and <italic>rad51d</italic> (<xref ref-type="bibr" rid="B23">23</xref>) knockout mutants to understand how the FA pathway influences spontaneous mutagenesis and to distinguish the roles of the FA and HRR pathways in mutation control. CHO cells have been widely used to perform highly quantitative mutagenesis studies at the <italic>hprt</italic> locus (<xref ref-type="bibr" rid="B39">39</xref>) and, using the <italic>dhfr</italic> locus to analyze gene amplification, to assay a specific type of carcinogenic mutagenesis (<xref ref-type="bibr" rid="B40">40</xref>). We find both a &#x02018;reduced&#x02019; rate of occurrence of viable <italic>hprt</italic> mutants and &#x02018;increased&#x02019; rates of gene amplification in <italic>fancg</italic> cells. In addition, we compare the spectra of <italic>hprt</italic> mutations in the <italic>fancg</italic> and <italic>rad51d</italic> mutant lines with those of their gene-complemented control cells. These comparisons of mutation rate and spectrum in this model genetic system reveal fundamental differences between the contributions of the FA and HRR pathways in preventing mutagenesis. Our findings suggest that the FA pathway may deal with spontaneous DNA damage by promoting efficient DNA end joining as well as TLS and HRR.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Cell culture</title><p>Cells lines used were the CHO parental AA8 cells (<xref ref-type="bibr" rid="B41">41</xref>), the <italic>fancg</italic> knockout line (KO40), the hamster <italic>Fancg</italic>-complemented KO40 cells (40BP6) (<xref ref-type="bibr" rid="B38">38</xref>), the <italic>rad51d</italic> knockout cell line (51D1) and the hamster <italic>Rad51d</italic>-complemented 51D1 cells (51D1.3) (<xref ref-type="bibr" rid="B23">23</xref>). Cells were grown in monolayer or suspension culture in &#x003b1;MEM supplemented with 10% fetal bovine serum and antibiotics (<xref ref-type="bibr" rid="B41">41</xref>).</p></sec><sec><title>Mutation and gene amplification rates</title><p>Mutation rate was determined by fluctuation analysis (<xref ref-type="bibr" rid="B42">42</xref>). For <italic>hprt</italic> mutants, replica cultures were seeded with 500 cells and grown in suspension to 1&#x02013;2&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells/replica, plated and incubated under 6S-Gua selection (<xref ref-type="bibr" rid="B41">41</xref>). <italic>Hprt, dhfr</italic> and <italic>CAD</italic> mutation rates were calculated using the Poisson P<sub>0</sub> term (<xref ref-type="bibr" rid="B42">42</xref>), the maximum likelihood method (<xref ref-type="bibr" rid="B43">43</xref>) and the method of the mean (<xref ref-type="bibr" rid="B44">44</xref>). To recover cells having amplified <italic>dhfr</italic> or <italic>CAD</italic> genes, selection was done in 300 nM methotrexate or in 360&#x02009;&#x000b5;M <italic>N</italic>-(phosphonacetyl)-<italic>L</italic>-aspartate (PALA) and 1&#x02009;&#x000b5;M dipyridimole, respectively. Verification of <italic>cad</italic> gene amplification was done using real-time, quantitative PCR analysis. Equal numbers of cells from 10 PALA resistant colonies, picked in fluctuation tests, were pooled and genomic DNA isolated. The comparative threshold cycle (C<sub>T</sub>) method was used to quantify relative gene copy number between the <italic>CAD</italic> loci in DNA of PALA-resistant cell pools and in DNA isolated from stock populations. C<sub>T</sub> values, defined as the cycle number at which fluorescence of the reporter dye becomes higher than the background level, were determined for the target (<italic>CAD</italic>) and an internal reference (<italic>APE1</italic>) in each sample. The relative gene copy number of the <italic>CAD</italic> locus of the PALA resistant (PALA-R) clones versus the stock cells was calculated as 2<sup>&#x02212;&#x00394;&#x00394;CT</sup>, where &#x00394;&#x00394;C<sub>T</sub>&#x02009;=&#x02009;&#x00394;C<sub>T</sub><sup>PALA-R</sup> -&#x00394;C<sub>T</sub><sup>Stock</sup> and each &#x00394;C<sub>T</sub>&#x02009;=&#x02009;C<sub>T</sub><sup>CAD</sup>&#x02009;&#x02212;&#x02009;C<sub>T</sub><sup>APE1</sup>. PCR reactions for both primer sets and all DNA samples were performed in triplicate with the DyNAmo&#x02122; SYBR&#x000ae; Green qPCR enzyme kit (Finnzymes). PCR and fluorescence detection was performed by the DNA Engine Opticon (MJ Research). Fluorescence and sample comparison was done with Opticon MONITOR analysis software.</p></sec><sec><title>Hprt mutation spectrum analysis</title><p>After nine days incubation, independent 6S-Gua-resistant clones were isolated for <italic>hprt</italic> mutation analysis in a three-step process: (i) Gene disrupting mutations of <italic>hprt</italic> were determined by RT&#x02013;PCR of the <italic>hprt</italic> gene transcript and sequencing. After outgrowth of the 6S-Gua resistant clones, RNA was isolated using the RNeasy Mini Kit (Qiagen, Inc. Valencia, CA, USA), and cDNA was made by RT&#x02013;PCR using SuperScript III First-Strand Synthesis System for RT&#x02013;PCR (Invitrogen Corp. Carlsbad, CA, USA), and subsequent amplification using the forward primer 5&#x02032; TTCCTCCTCACACCGCTCTT, located 47&#x02009;bp upstream of the <italic>hprt</italic> start codon (exon 1), and reverse primer 5&#x02032; TGCAGATTCAACTTGAACTCTC, located 3&#x02009;bp downstream of the <italic>hprt</italic> termination codon (exon 9). PCR-amplified cDNAs were sent for sequencing (Elim Biopharmaceuticals, Inc. Hayward, CA, USA), using the forward and reverse primers noted above. (ii) Genomic DNA was isolated (QiaAmp DNA Blood Mini Kit, Qiagen, Inc.) from all clones without RT&#x02013;PCR products and tested for the presence of exons 1 and 9 (RT&#x02013;PCR primer sites) by PCR amplification with the primers: exon 1 forward: 5&#x02032; CCTCACCGCTTTCTCGTGCC (3&#x02009;bp from 5&#x02032; end of exon); exon 1 reverse 5&#x02032; CACGACGCTGGGGCTGCGGG (last bp of 3&#x02032; end of exon 1); exon 9 forward 5&#x02032; GTGAAACTGGGAAAGCCAAA (17&#x02009;bp from 5&#x02032; end of exon 9); exon 9 reverse 5&#x02032; TGAAAGAATCCAAGTGGGAAA (56&#x02009;bp from 3&#x02032; end of exon 9. (iii) Genomic DNA was isolated for all clones missing exons from the sequence of the RT&#x02013;PCR product, and tested for the presence of the exons by PCR. Primer pairs used to verify of the presence of the following exons were: Exons 2 and 3, forward: 5&#x02032; TGATGAACCAGGCTATGACC, located in exon2, and reverse: 5&#x02032; AATCCAGCAGGTCAGCAAAG located in exon 3; Exon 4, forward: 5&#x02032; TGATCAGTCAACAGGGGACA, located at the 5&#x02032; end of exon 4, and reverse: 5&#x02032; TTGAGAGATCATCCCCACCA, located at the 3&#x02032;end of exon 4; Exons 6, 7 and 8, forward: 5&#x02032; CAATGCAAACTCTGCTTTCC, located at the 5&#x02032; end of exon 6, an additional confirmation forward primer 5&#x02032; CTGGTGAAAAGGACCTCTCG, located at the 5&#x02032; end of exon7, and reverse: 5&#x02032; TCATTATAG T CAAGGGCATATCCA, located at the 3&#x02032; end of exon 8. All primers were synthesized by (Qiagen Inc. Valencia, CA, USA).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Reduced occurrence of spontaneous <italic>hprt</italic> mutants in <italic>fancg</italic> cells</title><p>Given the finding of abnormally low frequencies of viable <italic>hprt</italic> mutants in human FA lymphoblasts treated with psoralens (<xref ref-type="bibr" rid="B45">45</xref>,<xref ref-type="bibr" rid="B46">46</xref>), we wished to determine whether the <italic>spontaneous mutation rate</italic> (the calculated probability that a mutation arises in a cell's division cycle) is also altered in <italic>fancg</italic> CHO cells and the relevance of any observed changes to chromosome instability. Although spontaneous frequencies (frequency&#x02009;=&#x02009;fraction of cell population that is mutant) of viable <italic>hprt</italic> mutants were reported to be either normal or elevated in FA cells (<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B46">46</xref>,<xref ref-type="bibr" rid="B47">47</xref>) (perhaps reflecting variation in culture history), mutation <italic>rates</italic> have not been reported. For rate measurements, small, <italic>hprt</italic>-mutant-free replicate cultures were expanded to &#x0223c;10<sup>6</sup> cells, counted and then selected in 6S-Gua medium, which is toxic to cells having functional <italic>hprt</italic>. Cells with mutations in the <italic>hprt</italic> locus formed visible, countable colonies, from which mutation rates were calculated by classical Luria&#x02013;Delbr&#x000fc;ck fluctuation analysis.</p><p>The mutation rate for viable mutants was reduced by &#x0003e;67% in <italic>fancg</italic> (KO40) cells compared to both the parental AA8 and the <italic>Fancg</italic>-complemented cells (40BP6), based on the average of the three statistical methods of calculation (<xref ref-type="table" rid="T1">Table 1</xref>). This reduction is statistically significant [<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 for mutation rates calculated by each method (<xref ref-type="bibr" rid="B42 B43 B44">42&#x02013;44</xref>)]. Thus, the reduction in mutation rate in <italic>fancg</italic> cells suggests that most of the mutational events that would lead to viable <italic>hprt</italic> mutants in wild-type cells are lethal in <italic>fancg</italic> cells due to conversion to large deletions or rearrangements. The reduced recovery of <italic>fancg</italic> cells is not explained by reduced plating efficiency since the plating efficiency of KO40 is 84% versus 90% for AA8 and 40BP6 (<xref ref-type="bibr" rid="B38">38</xref>). Although the high concentration of 6S-Gua used for selection of <italic>hprt</italic> mutants (2&#x02009;&#x000b5;g/ml) far exceeds the levels at which cell survival assays are done, we tested the possibility that increased sensitivity of KO40 cells to 6S-Gua (<xref ref-type="bibr" rid="B38">38</xref>) might affect the outcome of the mutation rate analyses by measuring mutant frequencies at both 2&#x02009;&#x000b5;g/ml (the standard concentration) and 0.4&#x02009;&#x000b5;g/ml 6S-Gua (the equitoxic dose relative to AA8 cells at 2&#x02009;&#x000b5;g/ml). There was little difference in the frequency between the two doses (2.2&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;5</sup> versus 2.7&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;5</sup>, respectively), which implies <italic>hprt</italic> mutant recovery is unrelated to <italic>Fancg</italic> status.
<table-wrap id="T1" position="float"><label>Table 1.</label><caption><p>Rate of occurrence of viable <italic>hprt</italic> mutants in <italic>fancg</italic> (KO40) cells versus parental (AA8) and <italic>Fancg</italic>-complemented cells (40BP6)</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1">Cell line</th><th colspan="3" rowspan="1">Mutations per cell per generation (units&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;7</sup>) calculated by method of:</th></tr><tr><th rowspan="1" colspan="1"/><th colspan="3" rowspan="1"><hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">P<sub>0</sub></th><th rowspan="1" colspan="1">Maximum likelihood</th><th rowspan="1" colspan="1">Mean</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">AA8 (<xref ref-type="bibr" rid="B6">6</xref>)<xref ref-type="table-fn" rid="TF1"><sup>a</sup></xref></td><td rowspan="1" colspan="1">1.0&#x02009;&#x000b1;&#x02009;0.1<xref ref-type="table-fn" rid="TF1"><sup>b</sup></xref></td><td rowspan="1" colspan="1">1.5&#x02009;&#x000b1;&#x02009;0.3</td><td rowspan="1" colspan="1">7&#x02009;&#x000b1;&#x02009;1</td></tr><tr><td rowspan="1" colspan="1">KO40 (<xref ref-type="bibr" rid="B5">5</xref>)</td><td rowspan="1" colspan="1">&#x0003c;0.4&#x02009;&#x000b1;&#x02009;0.1<xref ref-type="table-fn" rid="TF1"><sup>c</sup></xref></td><td rowspan="1" colspan="1">&#x0003c;0.5&#x02009;&#x000b1;&#x02009;0.1</td><td rowspan="1" colspan="1">&#x0003c;2&#x02009;&#x000b1;&#x02009;0.3</td></tr><tr><td rowspan="1" colspan="1">40BP6 (<xref ref-type="bibr" rid="B5">5</xref>)</td><td rowspan="1" colspan="1">0.8&#x02009;&#x000b1;&#x02009;0.1</td><td rowspan="1" colspan="1">1.3&#x02009;&#x000b1;&#x02009;0.2</td><td rowspan="1" colspan="1">4&#x02009;&#x000b1;&#x02009;1</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p><sup>a</sup>The number in parenthesis is the number of times the experiment was performed; each experiment had 12 replicate dishes. <sup>b</sup>SEM. <sup>c</sup>Since no 6S-Gua-resistant colonies were recovered in two of the five KO40 experiments (indicated by &#x02018;&#x0003c;&#x02019;), these are conservative estimates of the rates. These values are significantly different (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) from the AA8 value using a <italic>t</italic>-test.</p></fn></table-wrap-foot></table-wrap></p><p>Thus, we infer that although the observed rate of occurrence of viable mutants is reduced in <italic>fancg</italic> cells, the true rate of gene disruption mutagenesis may be the same, or even increased, as in the HRR-deficient CHO cells, but with a high proportion of the events falling into a lethal class of mutation and remaining undetected.</p></sec><sec><title>Increased proportion of deletions in spontaneous <italic>hprt</italic> mutants of <italic>fancg</italic> cells</title><p>Since the spontaneous rate of forming viable <italic>hprt</italic> mutants was decreased in the <italic>fancg</italic> CHO cells, we wished to determine whether the spectrum of the recovered mutants could provide insight into the particular classes of mutation that were being converted into lethal events. Mutations were assigned to four classes (base substitution, deletion, insertion, splicing) based on analysis of mRNA and, in many cases, genomic DNA. &#x02018;Splicing&#x02019; mutations are those with alterations of mRNA whose causation was not identified by analysis of genomic DNA. For example, in clones showing loss of one or more exons in the RT&#x02013;PCR product sequence, genomic-DNA PCR amplification of the missing exon(s) was used to distinguish deletions of the exons from other splicing errors, referred to as exon skips. Another form of spicing error, leading to exon duplications in the mRNA, was also detected among some clones. It was reported that splicing alterations, which make up 12% of <italic>hprt</italic> mutations in a human database, are primarily base substitution mutations (<xref ref-type="bibr" rid="B48">48</xref>). However, since we are unable to classify the types of mutations leading to most exon skips and duplications, we consider them as a separate class of events referred to generically as &#x02018;splice mutants&#x02019; in our analysis. Consistent with previous studies in FA lymphoblasts compared with non-FA cells in response to psoralens (<xref ref-type="bibr" rid="B45">45</xref>,<xref ref-type="bibr" rid="B46">46</xref>), we found an almost statistically significant (<italic>P</italic>&#x02009;=&#x02009;0.052) increase in the proportion of <italic>hprt</italic> mutants that were deletions in the <italic>fancg</italic> cells (KO40; 21% base substitutions, 62% deletions, 2% insertions and 15% splice mutants; <italic>n</italic>&#x02009;=&#x02009;47, <xref ref-type="fig" rid="F1">Figure 1</xref>A) when compared to the <italic>Fancg</italic>-complemented control cells (40BP6; 31% base substitutions, 40% deletions, 11% insertions and 17% splice mutants; <italic>n</italic>&#x02009;=&#x02009;35, <xref ref-type="fig" rid="F1">Figure1</xref>B). This trend towards deletions was significant when compared to both complemented cell lines combined (<italic>P</italic>&#x02009;=&#x02009;0.02). Deletions in both KO40 and 40BP6 cell lines ranged in size from a few base pairs up to potentially the entire locus (as implied by no amplification of exon 1 and exon 9). Insertion mutations ranged in size from 1 to 4&#x02009;bp, of which all were duplications of local sequence and did not occur in nucleotide repeats (Supplementary Table 1).
<fig id="F1" position="float"><label>Figure 1.</label><caption><p>Proportion of base substitution (black), deletion (white), insertion (light gray), and splicing mutants (exon skips, duplications, and 17-bp deletions; dark gray) <italic>hprt</italic> mutations among clones of <italic>fancg</italic> KO40 cells (<bold>A</bold>), <italic>Fancg</italic> gene-corrected BP6 cells (<bold>B</bold>), <italic>rad51d</italic> 51D1 (<bold>C</bold>), and <italic>Rad51d</italic> gene-corrected 51D1.3 cells (<bold>D</bold>).</p></caption><graphic xlink:href="gkm315f1"/></fig></p></sec><sec><title>Excessive spontaneous <italic>hprt</italic> deletions in HRR-defective <italic>rad51d</italic> cells</title><p>Although our previous study discovered a high rate of <italic>hprt</italic> mutagenesis in CHO <italic>rad51d</italic> cells (&#x0223c;12&#x02013;fold elevated parental and gene-complemented cells) (<xref ref-type="bibr" rid="B23">23</xref>), the spectrum was not determined. We find that the <italic>rad51d</italic>-associated HRR deficiency leads to a large increase in deletions (86%, <italic>n</italic>&#x02009;=&#x02009;50, <xref ref-type="fig" rid="F1">Figure1</xref>C) and vast reduction in the proportion of base substitutions and insertions (2% each), with the remaining 10% of mutations being splice mutants, all exon skips. This proportion of deletions is significantly (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) different from the proportion in the <italic>Rad51d</italic>-complemented control cells (51D1.3), which have a mutant spectrum with 36% deletions, 40% base substitutions, 7% insertions and 25% splice mutants (<italic>n</italic>&#x02009;=&#x02009;40, <xref ref-type="fig" rid="F1">Figure 1</xref>D), similar to that of the 40BP6 cells. As seen in the <italic>fancg</italic> cells, <italic>rad51d hprt</italic> deletions ranged in size from 1&#x02009;bp to deletion of the entire locus. The description of each mutant is provided in Supplementary Table 1. For comparison, the <italic>hprt</italic> mutation spectrum in <italic>brca2</italic> V79 hamster cells (defective in the one known gene common to the FA and HRR pathways) also showed a spectrum shift toward more deletions (<xref ref-type="bibr" rid="B49">49</xref>) while showing only a moderate increase in spontaneous mutation rate (&#x0223c;4&#x02013;fold) (<xref ref-type="bibr" rid="B50">50</xref>).</p></sec><sec><title>Elevated gene amplification rates in <italic>fancg</italic> cells</title><p>Our inference that the <italic>fancg</italic> mutation results in aberrantly repaired DSBs during DNA replication suggested that the process of gene amplification, which is typically associated with conditions that cause inappropriate rejoining of DSBs (<xref ref-type="bibr" rid="B51">51</xref>,<xref ref-type="bibr" rid="B52">52</xref>), might be elevated in <italic>fancg</italic> cells, as seen previously in <italic>rad51d</italic> cells (<xref ref-type="bibr" rid="B23">23</xref>). To test this prediction, we measured gene amplification using the extensively studied <italic>dhfr</italic> locus (where an increased gene-copy number confers methotrexate resistance) and the <italic>CAD</italic> (carbamyl-<italic>P</italic>-synthetase, aspartate transcarbamylase, dihydro-orotase) locus where amplification confers PALA resistance. We find that rates of spontaneous gene amplification are substantially increased (3- to 4-fold) at both loci in <italic>fancg</italic> cells (<xref ref-type="fig" rid="F2">Figure 2</xref>), a change that is statistically significant for both loci in comparison to wild-type AA8 cells (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01 and <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 for the <italic>dhfr</italic> and <italic>CAD</italic> loci, respectively) and <italic>Fancg</italic>-corrected 40BP6 cells (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 and <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 for the <italic>dhfr</italic> and <italic>CAD</italic> loci, respectively). It has been shown previously that all PALA-resistant AA8 clones have detectable amplification at the <italic>CAD</italic> locus (<xref ref-type="bibr" rid="B51">51</xref>). We also verified amplification by measuring its &#x02018;extent&#x02019; at the <italic>CAD</italic> locus using quantitative PCR of genomic DNA from pools of 10 independent PALA-resistant clones. As expected, there was an increase in the relative number of <italic>CAD</italic> gene copies with respect to an internal-standard reference gene (<italic>APE1</italic> locus) when compared to the DNA from cells in the respective stock cultures. In wild-type cells, the fold increase normalized to <italic>APE1</italic> was 2.3&#x02009;&#x000b1;&#x02009;0.8 (SEM), while in <italic>fancg</italic> cells we found a 2.8-fold increase. Taken together, we infer that the extent of gene amplification was the same in those wild-type and <italic>fancg</italic> cells that were <italic>PALA</italic> resistant. Overall, the increased rate of mutagenesis in the form of gene amplification in <italic>fancg</italic> is consistent with increased aberrant repair of spontaneous DSBs, most likely during S phase. Interestingly, these results are similar to those seen in the <italic>rad51d</italic> CHO cells, which show even greater amplification at both reporter loci (<xref ref-type="bibr" rid="B23">23</xref>).
<fig id="F2" position="float"><label>Figure 2.</label><caption><p>Rate of amplification mutations at <italic>dhfr</italic> (methotrexate resistance) and <italic>CAD</italic> (PALA resistance) loci in <italic>fancg</italic> and control cells. Each methotrexate experiment was done three or four times with 20 replica cultures, and each PALA experiment was done twice with 20 replicates.</p></caption><graphic xlink:href="gkm315f2"/></fig></p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><sec><title>Implications of changes in spontaneous <italic>hprt</italic> mutation rate and spectrum in mutant lines</title><p>In the <italic>rad51d</italic> cells, the greatly increased yield of <italic>hprt</italic> mutants suggests a prominent role for this pathway in preventing frequent mutagenic events from occurring during normal DNA replication in the face of spontaneous (oxidative) lesions (<xref ref-type="bibr" rid="B23">23</xref>). Indeed, HRR was shown to act on collapsed replication forks caused by endogenous DNA single-strand breaks (<xref ref-type="bibr" rid="B53">53</xref>). In our study we found that the spectrum of mutations from <italic>rad51d</italic> cells reveals that the mutagenic events prevented by intact HRR are deletions, likely caused by efficient DNA end-joining mechanisms that repair DSBs that persist when broken replication forks are not restarted.</p><p>In the <italic>fancg</italic> CHO cells, we see a major reduction in the yield of four classes of spontaneous <italic>hprt</italic> mutants compared with wild-type. The reduced yield of both base substitution and deletion/insertion events in the <italic>fancg</italic> cells points to a role for Fancg and the FA proteins in promoting TLS at replication-blocking lesions (the source of base substitution mutations), as well as in coordinating HRR to restart broken replication forks and NHEJ to restore broken-fork-associated DSBs. The latter two processes are necessary events for assuring either conservative repair or recoverable <italic>hprt</italic> deletion mutants, respectively. There was a tendency toward more deletions among spontaneous mutations of the CHO <italic>fancg</italic> cells. It is interesting to note that the spectrum of spontaneous mutations in <italic>hprt</italic> in FA lymphoblasts and T-lymphocytes is also shifted toward more frequent deletions versus base substitutions (<xref ref-type="bibr" rid="B45 B46 B47">45&#x02013;47</xref>). In the <italic>fancg</italic> cells a high proportion of replication fork breaks, which in normal or <italic>rad51d</italic> cells often result in recoverable <italic>hprt</italic> mutants, must result in lethality to account for the reduced yield of viable mutants. The most likely source of this reduction is the failure to rejoin the breaks due to both impaired HRR and end joining, or by erroneous rejoining causing multigenic, lethal deletion or translocation (as depicted by the model in <xref ref-type="fig" rid="F3">Figure 3</xref> and discussed subsequently).
<fig id="F3" position="float"><label>Figure 3.</label><caption><p>Model of spontaneous <italic>hprt</italic> mutational outcome in wild-type, <italic>rad51d</italic> and <italic>fancg</italic> mutant cells during replication. Each panel represents one of the three genotypes: wild type, <italic>rad51d</italic> and <italic>fancg</italic>. On the right in each panel are shown the potential mutational outcomes due to a replication fork encountering a polymerase-blocking lesion (upper fork) or a single-strand break or gap such as a repair intermediate (lower fork). Arrows represent the options for resolving each situation, leading to the viable or lethal mutagenic events. <bold>Upper panel</bold>: In wild-type cells, there are two major outcomes (large green arrows): translesion synthesis (TLS) bypasses fork blocking lesions (sometimes leading to base substitution, &#x02018;m&#x02019;), and homologous recombination (HR) restarts broken replication forks and prevents mutations. <bold>Middle panel</bold>: The HR-defective <italic>rad51d</italic> cells, which are presumed to have normal TLS, inefficiently restart broken forks in an error-free manner, but retain efficient NHEJ activity, as evidenced by a high frequency and proportion of small-sized (non-lethal) deletions (large red arrow). NHEJ acts on replication-associated DSBs that arise when replication forks break and free-ends persist as replication continues. <bold>Lower panel</bold>: In the <italic>fancg</italic> cells, the reduced absolute number of base substitutions and small deletions, along with the increased rate of gene amplification, suggest diminished TLS and HR, as well as the loss of NHEJ activity that produces deletions that are recoverable in the <italic>hprt</italic> mutagenesis assay (as in <italic>rad51d</italic> cells). The predominant events in <italic>fancg</italic> cells appear to be inviable deletions or rearrangements (large red arrow).</p></caption><graphic xlink:href="gkm315f3"/></fig></p></sec><sec><title>Relevance of the FA pathway of gene amplification</title><p>Gene amplification is a type of mutation often associated with tumors and is elevated in cultured tumor cells versus non-tumorigenic cells (<xref ref-type="bibr" rid="B54">54</xref>,<xref ref-type="bibr" rid="B55">55</xref>). Many studies have shown the importance of DSBs in gene amplification although the mechanisms remain incompletely understood (<xref ref-type="bibr" rid="B55 B56 B57 B58">55&#x02013;58</xref>). Treatments with IR or H<sub>2</sub>O<sub>2</sub>, which cause lesions that include DSBs, enhance gene amplification (<xref ref-type="bibr" rid="B52">52</xref>). CHO cells defective in NHEJ due to a <italic>DNA-PKcs</italic> mutation have greatly elevated (20- to 150-fold) amplification (<xref ref-type="bibr" rid="B51">51</xref>), while the <italic>rad51d</italic> cells show 4- to 10-fold increases (<xref ref-type="bibr" rid="B23">23</xref>).</p><p>Our findings of 3- to 4-fold increased gene amplification in the <italic>fancg</italic> cells support the idea that DSBs arising during DNA replication are aberrantly repaired. The breakage&#x02013;fusion-bridge mechanism of amplification is a popular model (<xref ref-type="bibr" rid="B59">59</xref>), in which the amplification process may be initiated by a DSB that arises during replication and persists until being removed by end joining between sister chromatids. During the next anaphase, an asymmetrical mechanical break in the dicentric &#x02018;bridge&#x02019; chromosome can then result in duplication of the target gene in one daughter cell. This process can be repeated in subsequent mitoses.</p></sec><sec><title>Model of spontaneous mutational outcomes in wild-type and FA and HRR mutant cells</title><p>It is noteworthy that <italic>fancg</italic> CHO cells are hypersensitive to killing by a variety of mutagens besides crosslinking agents, i.e. &#x003b3;-rays, methyl methanesulfonate, methylnitrosourea, ethylnitrosourea and 6S-Gua (<xref ref-type="bibr" rid="B38">38</xref>). This finding implies that loss of Fancg and, consequently, Fancd2 monoubiquitination, causes a defect in dealing with a much broader class of DNA damage than simply inter-strand crosslinking, e.g. oxidative and alkylation lesions commonly caused by normal cellular metabolism. Induced mutagenesis data also support a role for FA proteins in promoting replication past a variety of DNA lesions, as the <italic>fancg</italic> cells have decreased recovery of <italic>hprt</italic> mutants after exposure to various DNA damaging agents, including UV-C, &#x003b3;-rays and ethylnitrosourea, relative to the parental control cells (<xref ref-type="bibr" rid="B33">33</xref>). The unusually high sensitivity of <italic>fancg</italic> cells (<xref ref-type="bibr" rid="B38">38</xref>) (and FA cells generally) to crosslinking agents may be explained by the unique, dual requirement for TLS and HRR to bring about repair of broken replication forks resulting from cross-link processing.</p><p>In summary, our gene amplification and <italic>hprt</italic> mutation studies emphasize both similarities and marked differences in phenotype between the FA and HRR mutants in an isogenic mammalian system. Our data combined with that in the literature support a model in which FANCD2 monoubiquitination acts upstream of TLS, HRR and NHEJ by supporting <italic>all three processes</italic> during S phase in response to endogenous and exogenous DNA damage (<xref ref-type="fig" rid="F3">Figure 3</xref>). Although endogenous inter-strand crosslinks may contribute to the FA phenotype, our induced mutagenesis and survival studies argue that the FANC pathway is more globally important for diverse lesions (<xref ref-type="bibr" rid="B33">33</xref>). We conclude that pathway coordination by FA proteins supports a &#x02018;Fire Captain&#x02019; model (<xref ref-type="bibr" rid="B33">33</xref>), in which they act to limit the severity of mutagenesis by promoting efficient TLS, HRR and NHEJ.</p></sec></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>[Supplementary Material]</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="nar_gkm315_index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="msword"
xlink:href="nar_gkm315_nar-00558-d-2007-File002.doc"/>
</supplementary-material>
</sec>
</body><back><ack><title>ACKOWLEDGEMENTS</title><p>The authors would like to thank Vicki Kopf, Lynn Carr and Tricia Allen for technical assistance and Maureen Hoatlin for extensive comments on the manuscript. They also thank the Drug Synthesis and Chemistry Branch, Division of Cancer Treatment, National Cancer Institute, for providing PALA. This work was performed under the auspices of the US Department of Energy by the University of California, Lawrence Livermore National Laboratory under Contract No. W-7405-Eng-48. The DOE Low-Dose Program and NCI/NIH grants CA89405 and CA112566 funded this work. Funding to pay the Open Access publication charges for this article was provided by NIH grant CA112566.</p><p><italic>Conflict of interest statement</italic>. None declared.</p></ack><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alter</surname><given-names>BP</given-names></name></person-group><article-title>Fanconi's anemia and malignancies</article-title><source>Am. J. Hematol</source><year>1996</year><volume>53</volume><fpage>99</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">8892734</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joenje</surname><given-names>H</given-names></name><name><surname>Patel</surname><given-names>KJ</given-names></name></person-group><article-title>The emerging genetic and molecular basis of Fanconi anaemia</article-title><source>Nat. Rev. Genet</source><year>2001</year><volume>2</volume><fpage>446</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">11389461</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>LH</given-names></name></person-group><article-title>Unraveling the Fanconi anemia&#x02013;DNA repair connection</article-title><source>Nat. Genet</source><year>2005</year><volume>37</volume><fpage>921</fpage><lpage>922</lpage><pub-id pub-id-type="pmid">16132046</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niedernhofer</surname><given-names>LJ</given-names></name><name><surname>Lalai</surname><given-names>AS</given-names></name><name><surname>Hoeijmakers</surname><given-names>JH</given-names></name></person-group><article-title>Fanconi Anemia (Cross)linked to DNA Repair</article-title><source>Cell</source><year>2005</year><volume>123</volume><fpage>1191</fpage><lpage>1198</lpage><pub-id pub-id-type="pmid">16377561</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>RD</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name></person-group><article-title>The Fanconi Anemia/BRCA pathway: new faces in the crowd</article-title><source>Genes Dev</source><year>2005</year><volume>19</volume><fpage>2925</fpage><lpage>2940</lpage><pub-id pub-id-type="pmid">16357213</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciccia</surname><given-names>A</given-names></name><name><surname>Ling</surname><given-names>C</given-names></name><name><surname>Coulthard</surname><given-names>R</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Meetei</surname><given-names>AR</given-names></name><name><surname>Laghmani el</surname><given-names>H</given-names></name><name><surname>Joenje</surname><given-names>H</given-names></name><name><surname>McDonald</surname><given-names>N</given-names></name><etal/></person-group><article-title>Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM</article-title><source>Mol. Cell</source><year>2007</year><volume>25</volume><fpage>331</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">17289582</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>C</given-names></name><name><surname>Ishiai</surname><given-names>M</given-names></name><name><surname>Ali</surname><given-names>AM</given-names></name><name><surname>Medhurst</surname><given-names>AL</given-names></name><name><surname>Neveling</surname><given-names>K</given-names></name><name><surname>Kalb</surname><given-names>R</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Oostra</surname><given-names>AB</given-names></name><etal/></person-group><article-title>FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway</article-title><source>EMBO J</source><year>2007</year><volume>26</volume><fpage>2104</fpage><lpage>2114</lpage><pub-id pub-id-type="pmid">17396147</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Garcia-Higuera</surname><given-names>I</given-names></name><name><surname>Andreassen</surname><given-names>PR</given-names></name><name><surname>Gregory</surname><given-names>RC</given-names></name><name><surname>Grompe</surname><given-names>M</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name></person-group><article-title>S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51</article-title><source>Blood</source><year>2002</year><volume>100</volume><fpage>2414</fpage><lpage>2420</lpage><pub-id pub-id-type="pmid">12239151</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>LH</given-names></name><name><surname>Schild</surname><given-names>D</given-names></name></person-group><article-title>Homologous recombinational repair of DNA ensures mammalian chromosome stability</article-title><source>Mutat. Res</source><year>2001</year><volume>477</volume><fpage>131</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">11376695</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helleday</surname><given-names>T</given-names></name></person-group><article-title>Pathways for mitotic homologous recombination in mammalian cells</article-title><source>Mutat. Res</source><year>2003</year><volume>532</volume><fpage>103</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">14643432</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thacker</surname><given-names>J</given-names></name></person-group><article-title>The RAD51 gene family, genetic instability and cancer</article-title><source>Cancer Lett</source><year>2005</year><volume>219</volume><fpage>125</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">15723711</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howlett</surname><given-names>NG</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Olson</surname><given-names>S</given-names></name><name><surname>Cox</surname><given-names>B</given-names></name><name><surname>Waisfisz</surname><given-names>Q</given-names></name><name><surname>De Die-Smulders</surname><given-names>C</given-names></name><name><surname>Persky</surname><given-names>N</given-names></name><name><surname>Grompe</surname><given-names>M</given-names></name><name><surname>Joenje</surname><given-names>H</given-names></name><etal/></person-group><article-title>Biallelic inactivation of BRCA2 in Fanconi anemia</article-title><source>Science</source><year>2002</year><volume>297</volume><fpage>606</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">12065746</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>JB</given-names></name><name><surname>Blom</surname><given-names>E</given-names></name><name><surname>Thompson</surname><given-names>LH</given-names></name><name><surname>Sung</surname><given-names>P</given-names></name><name><surname>Gordon</surname><given-names>SM</given-names></name><name><surname>Kupfer</surname><given-names>GM</given-names></name><name><surname>Joenje</surname><given-names>H</given-names></name><name><surname>Mathew</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Tetratricopeptide-motif-mediated interaction of FANCG with recombination proteins XRCC3 and BRCA2</article-title><source>DNA Repair</source><year>2006</year><volume>5</volume><fpage>629</fpage><lpage>640</lpage><pub-id pub-id-type="pmid">16621732</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>German</surname><given-names>J</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Spatz</surname><given-names>L</given-names></name><name><surname>Bloom</surname><given-names>AD</given-names></name><name><surname>Paul</surname><given-names>NW</given-names></name></person-group><article-title>The chromosome-breakage syndromes: rare disorders that provide models for studying somatic mutation</article-title><source>Detection of Cancer Predisposition: laboratory Approaches, March of Dimes Birth Defects Foundation</source><year>1990</year><publisher-loc>NY</publisher-loc><publisher-name>White Plains</publisher-name><fpage>85</fpage><lpage>111</lpage></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Andrea</surname><given-names>AD</given-names></name><name><surname>Grompe</surname><given-names>M</given-names></name></person-group><article-title>The Fanconi anaemia/BRCA pathway</article-title><source>Nat. Rev. Cancer</source><year>2003</year><volume>3</volume><fpage>23</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">12509764</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newell</surname><given-names>AE</given-names></name><name><surname>Akkari</surname><given-names>YM</given-names></name><name><surname>Torimaru</surname><given-names>Y</given-names></name><name><surname>Rosenthal</surname><given-names>A</given-names></name><name><surname>Reifsteck</surname><given-names>CA</given-names></name><name><surname>Cox</surname><given-names>B</given-names></name><name><surname>Grompe</surname><given-names>M</given-names></name><name><surname>Olson</surname><given-names>SB</given-names></name></person-group><article-title>Interstrand crosslink-induced radials form between non-homologous chromosomes, but are absent in sex chromosomes</article-title><source>DNA Repair</source><year>2004</year><volume>3</volume><fpage>535</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">15084315</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>LH</given-names></name><name><surname>Hinz</surname><given-names>JM</given-names></name><name><surname>Yamada</surname><given-names>NA</given-names></name><name><surname>Jones</surname><given-names>NJ</given-names></name></person-group><article-title>How Fanconi anemia proteins promote the four Rs: Replication, recombination, repair, and recovery</article-title><source>Environ. Mol. Mutagen</source><year>2005</year><volume>45</volume><fpage>128</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">15668941</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lees-Miller</surname><given-names>SP</given-names></name><name><surname>Meek</surname><given-names>K</given-names></name></person-group><article-title>Repair of DNA double strand breaks by non-homologous end joining</article-title><source>Biochimie</source><year>2003</year><volume>85</volume><fpage>1161</fpage><lpage>1173</lpage><pub-id pub-id-type="pmid">14726021</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hefferin</surname><given-names>ML</given-names></name><name><surname>Tomkinson</surname><given-names>AE</given-names></name></person-group><article-title>Mechanism of DNA double-strand break repair by non-homologous end joining</article-title><source>DNA Repair</source><year>2005</year><volume>4</volume><fpage>639</fpage><lpage>648</lpage><pub-id pub-id-type="pmid">15907771</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veuger</surname><given-names>SJ</given-names></name><name><surname>Curtin</surname><given-names>NJ</given-names></name><name><surname>Richardson</surname><given-names>CJ</given-names></name><name><surname>Smith</surname><given-names>GC</given-names></name><name><surname>Durkacz</surname><given-names>BW</given-names></name></person-group><article-title>Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>6008</fpage><lpage>6015</lpage><pub-id pub-id-type="pmid">14522929</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Audebert</surname><given-names>M</given-names></name><name><surname>Salles</surname><given-names>B</given-names></name><name><surname>Calsou</surname><given-names>P</given-names></name></person-group><article-title>Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining</article-title><source>J. Biol. Chem</source><year>2004</year><volume>279</volume><fpage>55117</fpage><lpage>55126</lpage><pub-id pub-id-type="pmid">15498778</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>LH</given-names></name><name><surname>Schild</surname><given-names>D</given-names></name></person-group><article-title>Recombinational DNA repair and human disease</article-title><source>Mutat. Res</source><year>2002</year><volume>509</volume><fpage>49</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">12427531</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinz</surname><given-names>JM</given-names></name><name><surname>Tebbs</surname><given-names>RS</given-names></name><name><surname>Wilson</surname><given-names>PF</given-names></name><name><surname>Nham</surname><given-names>PB</given-names></name><name><surname>Salazar</surname><given-names>EP</given-names></name><name><surname>Nagasawa</surname><given-names>H</given-names></name><name><surname>Urbin</surname><given-names>SS</given-names></name><name><surname>Bedford</surname><given-names>JS</given-names></name><name><surname>Thompson</surname><given-names>LH</given-names></name></person-group><article-title>Repression of mutagenesis by Rad51D-mediated homologous recombination</article-title><source>Nucleic Acids Res</source><year>2006</year><volume>34</volume><fpage>1358</fpage><lpage>1368</lpage><pub-id pub-id-type="pmid">16522646</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Ishiai</surname><given-names>M</given-names></name><name><surname>Matsushita</surname><given-names>N</given-names></name><name><surname>Arakawa</surname><given-names>H</given-names></name><name><surname>Lamerdin</surname><given-names>JE</given-names></name><name><surname>Buerstedde</surname><given-names>JM</given-names></name><name><surname>Tanimoto</surname><given-names>M</given-names></name><name><surname>Harada</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>LH</given-names></name><etal/></person-group><article-title>Fanconi anemia FANCG protein in mitigating radiation- and enzyme-induced DNA double-strand breaks by homologous recombination in vertebrate cells</article-title><source>Mol. Cell. Biol</source><year>2003</year><volume>23</volume><fpage>5421</fpage><lpage>5430</lpage><pub-id pub-id-type="pmid">12861027</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Hirano</surname><given-names>S</given-names></name><name><surname>Ishiai</surname><given-names>M</given-names></name><name><surname>Morishima</surname><given-names>K</given-names></name><name><surname>Kitao</surname><given-names>H</given-names></name><name><surname>Namikoshi</surname><given-names>K</given-names></name><name><surname>Kimura</surname><given-names>M</given-names></name><name><surname>Matsushita</surname><given-names>N</given-names></name><name><surname>Arakawa</surname><given-names>H</given-names></name><etal/></person-group><article-title>Fanconi anemia protein FANCD2 promotes immunoglobulin gene conversion and DNA repair through a mechanism related to homologous recombination</article-title><source>Mol. Cell. Biol</source><year>2005</year><volume>25</volume><fpage>34</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">15601828</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakanishi</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>YG</given-names></name><name><surname>Pierce</surname><given-names>AJ</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Digweed</surname><given-names>M</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name><name><surname>Wang</surname><given-names>ZQ</given-names></name><name><surname>Jasin</surname><given-names>M</given-names></name></person-group><article-title>Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2005</year><volume>102</volume><fpage>1110</fpage><lpage>1115</lpage><pub-id pub-id-type="pmid">15650050</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thyagarajan</surname><given-names>B</given-names></name><name><surname>Campbell</surname><given-names>C</given-names></name></person-group><article-title>Elevated homologous recombination activity in fanconi anemia fibroblasts</article-title><source>J. Biol. Chem</source><year>1997</year><volume>272</volume><fpage>23328</fpage><lpage>23333</lpage><pub-id pub-id-type="pmid">9287344</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donahue</surname><given-names>SL</given-names></name><name><surname>Lundberg</surname><given-names>R</given-names></name><name><surname>Saplis</surname><given-names>R</given-names></name><name><surname>Campbell</surname><given-names>C</given-names></name></person-group><article-title>Deficient regulation of DNA double-strand break repair in Fanconi anemia fibroblasts</article-title><source>J. Biol. Chem</source><year>2003</year><volume>278</volume><fpage>29487</fpage><lpage>29495</lpage><pub-id pub-id-type="pmid">12748186</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohashi</surname><given-names>A</given-names></name><name><surname>Zdzienicka</surname><given-names>MZ</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Couch</surname><given-names>FJ</given-names></name></person-group><article-title>FANCD2 functions independently of BRCA2 and RAD51 associated homologous recombination in response to DNA damage</article-title><source>J. Biol. Chem</source><year>2005</year><volume>280</volume><fpage>14877</fpage><lpage>14883</lpage><pub-id pub-id-type="pmid">15671039</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundberg</surname><given-names>R</given-names></name><name><surname>Mavinakere</surname><given-names>M</given-names></name><name><surname>Campbell</surname><given-names>C</given-names></name></person-group><article-title>Deficient DNA end joining activity in extracts from fanconi anemia fibroblasts</article-title><source>J. Biol. Chem</source><year>2001</year><volume>276</volume><fpage>9543</fpage><lpage>9549</lpage><pub-id pub-id-type="pmid">11124945</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donahue</surname><given-names>SL</given-names></name><name><surname>Campbell</surname><given-names>C</given-names></name></person-group><article-title>A DNA double strand break repair defect in Fanconi anemia fibroblasts</article-title><source>J. Biol. Chem</source><year>2002</year><volume>277</volume><fpage>46243</fpage><lpage>46247</lpage><pub-id pub-id-type="pmid">12361951</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donahue</surname><given-names>SL</given-names></name><name><surname>Campbell</surname><given-names>C</given-names></name></person-group><article-title>A Rad50-dependent pathway of DNA repair is deficient in Fanconi anemia fibroblasts</article-title><source>Nucleic Acids Res</source><year>2004</year><volume>32</volume><fpage>3248</fpage><lpage>3257</lpage><pub-id pub-id-type="pmid">15199173</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinz</surname><given-names>JM</given-names></name><name><surname>Nham</surname><given-names>PB</given-names></name><name><surname>Salazar</surname><given-names>EP</given-names></name><name><surname>Wilson</surname><given-names>PF</given-names></name><name><surname>Thompson</surname><given-names>LH</given-names></name></person-group><article-title>The Fanconi anemia pathway limits the severity of mutagenesis</article-title><source>DNA Repair</source><year>2006</year><volume>34</volume><fpage>1358</fpage><lpage>1368</lpage></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sala-Trepat</surname><given-names>M</given-names></name><name><surname>Boyse</surname><given-names>J</given-names></name><name><surname>Richard</surname><given-names>P</given-names></name><name><surname>Papadopoulo</surname><given-names>D</given-names></name><name><surname>Moustacchi</surname><given-names>E</given-names></name></person-group><article-title>Frequencies of HPRT- lymphocytes and glycophorin A variants erythrocytes in Fanconi anemia patients, their parents and control donors</article-title><source>Mutat. Res</source><year>1993</year><volume>289</volume><fpage>115</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">7689157</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evdokimova</surname><given-names>VN</given-names></name><name><surname>McLoughlin</surname><given-names>RK</given-names></name><name><surname>Wenger</surname><given-names>SL</given-names></name><name><surname>Grant</surname><given-names>SG</given-names></name></person-group><article-title>Use of the glycophorin A somatic mutation assay for rapid, unambiguous identification of Fanconi anemia homozygotes regardless of GPA genotype</article-title><source>Am. J. Med. Genet. A</source><year>2005</year><volume>135</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">15822129</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araten</surname><given-names>DJ</given-names></name><name><surname>Golde</surname><given-names>DW</given-names></name><name><surname>Zhang</surname><given-names>RH</given-names></name><name><surname>Thaler</surname><given-names>HT</given-names></name><name><surname>Gargiulo</surname><given-names>L</given-names></name><name><surname>Notaro</surname><given-names>R</given-names></name><name><surname>Luzzatto</surname><given-names>L</given-names></name></person-group><article-title>A quantitative measurement of the human somatic mutation rate</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>8111</fpage><lpage>8117</lpage><pub-id pub-id-type="pmid">16166284</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niedzwiedz</surname><given-names>W</given-names></name><name><surname>Mosedale</surname><given-names>G</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>Ong</surname><given-names>CY</given-names></name><name><surname>Pace</surname><given-names>P</given-names></name><name><surname>Patel</surname><given-names>KJ</given-names></name></person-group><article-title>The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair</article-title><source>Mol. Cell</source><year>2004</year><volume>15</volume><fpage>607</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">15327776</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tebbs</surname><given-names>RS</given-names></name><name><surname>Hinz</surname><given-names>JM</given-names></name><name><surname>Yamada</surname><given-names>NA</given-names></name><name><surname>Wilson</surname><given-names>JB</given-names></name><name><surname>Salazar</surname><given-names>EP</given-names></name><name><surname>Thomas</surname><given-names>CB</given-names></name><name><surname>Jones</surname><given-names>IM</given-names></name><name><surname>Jones</surname><given-names>NJ</given-names></name><name><surname>Thompson</surname><given-names>LH</given-names></name></person-group><article-title>New insights into the Fanconi anemia pathway from an isogenic FancG hamster CHO mutant</article-title><source>DNA Repair</source><year>2005</year><volume>4</volume><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">15533833</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Neill</surname><given-names>JP</given-names></name><name><surname>Hsie</surname><given-names>AW</given-names></name></person-group><article-title>Chemical mutagenesis of mammalian cells can be quantified</article-title><source>Nature</source><year>1977</year><volume>269</volume><fpage>815</fpage><lpage>817</lpage><pub-id pub-id-type="pmid">927508</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milbrandt</surname><given-names>JD</given-names></name><name><surname>Heintz</surname><given-names>NH</given-names></name><name><surname>White</surname><given-names>WC</given-names></name><name><surname>Rothman</surname><given-names>SM</given-names></name><name><surname>Hamlin</surname><given-names>JL</given-names></name></person-group><article-title>Methotrexate-resistant Chinese hamster ovary cells have amplified a 135-kilobase-pair region that includes the dihydrofolate reductase gene</article-title><source>Proc. Natl Acad. Sci. USA</source><year>1981</year><volume>78</volume><fpage>6043</fpage><lpage>6047</lpage><pub-id pub-id-type="pmid">6273843</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>LH</given-names></name><name><surname>Fong</surname><given-names>S</given-names></name><name><surname>Brookman</surname><given-names>K</given-names></name></person-group><article-title>Validation of conditions for efficient detection of HPRT and APRT mutations in suspension-cultured Chinese hamster cells</article-title><source>Mutat. Res</source><year>1980</year><volume>74</volume><fpage>21</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">7360155</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luria</surname><given-names>SE</given-names></name><name><surname>Delbr&#x000fc;ck</surname><given-names>M</given-names></name></person-group><article-title>Mutations of bacteria from virus sensitivity to virus resistance</article-title><source>Genetics</source><year>1943</year><volume>28</volume><fpage>491</fpage><lpage>511</lpage><pub-id pub-id-type="pmid">17247100</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Q</given-names></name></person-group><article-title>Update on estimation of mutation rates using data from fluctuation experiments</article-title><source>Genetics</source><year>2005</year><volume>171</volume><fpage>861</fpage><lpage>864</lpage><pub-id pub-id-type="pmid">16020795</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capizzi</surname><given-names>RL</given-names></name><name><surname>Jameson</surname><given-names>JW</given-names></name></person-group><article-title>A table for the estimation of the spontaneous mutation rate of cells in culture</article-title><source>Mutat. Res</source><year>1973</year><volume>17</volume><fpage>147</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">4682600</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papadopoulo</surname><given-names>D</given-names></name><name><surname>Porfirio</surname><given-names>B</given-names></name><name><surname>Moustacchi</surname><given-names>E</given-names></name></person-group><article-title>Mutagenic response of Fanconi's anemia cells from a defined complementation group after treatment with photoactivated bifunctional psoralens</article-title><source>Cancer Res</source><year>1990</year><volume>50</volume><fpage>3289</fpage><lpage>3294</lpage><pub-id pub-id-type="pmid">2159378</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papadopoulo</surname><given-names>D</given-names></name><name><surname>Guillouf</surname><given-names>C</given-names></name><name><surname>Mohrenweiser</surname><given-names>H</given-names></name><name><surname>Moustacchi</surname><given-names>E</given-names></name></person-group><article-title>Hypomutability in Fanconi anemia cells is associated with increased deletion frequency at the HPRT locus</article-title><source>Proc. Natl Acad. Sci. USA</source><year>1990</year><volume>87</volume><fpage>8383</fpage><lpage>8387</lpage><pub-id pub-id-type="pmid">2236046</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laquerbe</surname><given-names>A</given-names></name><name><surname>Sala-Trepat</surname><given-names>M</given-names></name><name><surname>Vives</surname><given-names>C</given-names></name><name><surname>Escarceller</surname><given-names>M</given-names></name><name><surname>Papadopoulo</surname><given-names>D</given-names></name></person-group><article-title>Molecular spectra of HPRT deletion mutations in circulating T-lymphocytes in Fanconi anemia patients</article-title><source>Mutat. Res</source><year>1999</year><volume>431</volume><fpage>341</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">10635999</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Neill</surname><given-names>JP</given-names></name><name><surname>Rogan</surname><given-names>PK</given-names></name><name><surname>Cariello</surname><given-names>N</given-names></name><name><surname>Nicklas</surname><given-names>JA</given-names></name></person-group><article-title>Mutations that alter RNA splicing of the human HPRT gene: a review of the spectrum</article-title><source>Mutat. Res</source><year>1998</year><volume>411</volume><fpage>179</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">9804951</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraakman-van der Zwet</surname><given-names>M</given-names></name><name><surname>Overkamp</surname><given-names>WJ</given-names></name><name><surname>van Lange</surname><given-names>RE</given-names></name><name><surname>Essers</surname><given-names>J</given-names></name><name><surname>van Duijn-Goedhart</surname><given-names>A</given-names></name><name><surname>Wiggers</surname><given-names>I</given-names></name><name><surname>Swaminathan</surname><given-names>S</given-names></name><name><surname>van Buul</surname><given-names>PP</given-names></name><name><surname>Errami</surname><given-names>A</given-names></name><etal/></person-group><article-title>Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions</article-title><source>Mol. Cell. Biol</source><year>2002</year><volume>22</volume><fpage>669</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">11756561</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraakman-Van Der Zwet</surname><given-names>M</given-names></name><name><surname>Wiegant</surname><given-names>WW</given-names></name><name><surname>Zdzienicka</surname><given-names>MZ</given-names></name></person-group><article-title>Brca2 (XRCC11) deficiency results in enhanced mutagenesis</article-title><source>Mutagenesis</source><year>2003</year><volume>18</volume><fpage>521</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">14614187</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mondello</surname><given-names>C</given-names></name><name><surname>Rebuzzini</surname><given-names>P</given-names></name><name><surname>Dolzan</surname><given-names>M</given-names></name><name><surname>Edmonson</surname><given-names>S</given-names></name><name><surname>Taccioli</surname><given-names>GE</given-names></name><name><surname>Giulotto</surname><given-names>E</given-names></name></person-group><article-title>Increased gene amplification in immortal rodent cells deficient for the DNA-dependent protein kinase catalytic subunit</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>4520</fpage><lpage>4525</lpage><pub-id pub-id-type="pmid">11389084</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mondello</surname><given-names>C</given-names></name><name><surname>Guasconi</surname><given-names>V</given-names></name><name><surname>Giulotto</surname><given-names>E</given-names></name><name><surname>Nuzzo</surname><given-names>F</given-names></name></person-group><article-title>Gamma-ray and hydrogen peroxide induction of gene amplification in hamster cells deficient in DNA double strand break repair</article-title><source>DNA Repair</source><year>2002</year><volume>1</volume><fpage>483</fpage><lpage>493</lpage><pub-id pub-id-type="pmid">12509235</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saleh-Gohari</surname><given-names>N</given-names></name><name><surname>Bryant</surname><given-names>HE</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Parker</surname><given-names>KM</given-names></name><name><surname>Cassel</surname><given-names>TN</given-names></name><name><surname>Helleday</surname><given-names>T</given-names></name></person-group><article-title>Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks</article-title><source>Mol. Cell. Biol</source><year>2005</year><volume>25</volume><fpage>7158</fpage><lpage>7169</lpage><pub-id pub-id-type="pmid">16055725</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tlsty</surname><given-names>TD</given-names></name><name><surname>Margolin</surname><given-names>BH</given-names></name><name><surname>Lum</surname><given-names>K</given-names></name></person-group><article-title>Differences in the rates of gene amplification in nontumorigenic and tumorigenic cell lines as measured by Luria-Delbruck fluctuation analysis</article-title><source>Proc. Natl Acad. Sci. USA</source><year>1989</year><volume>86</volume><fpage>9441</fpage><lpage>9445</lpage><pub-id pub-id-type="pmid">2687881</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albertson</surname><given-names>DG</given-names></name></person-group><article-title>Gene amplification in cancer</article-title><source>Trends Genet</source><year>2006</year><volume>22</volume><fpage>447</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">16787682</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poupon</surname><given-names>MF</given-names></name><name><surname>Smith</surname><given-names>KA</given-names></name><name><surname>Chernova</surname><given-names>OB</given-names></name><name><surname>Gilbert</surname><given-names>C</given-names></name><name><surname>Stark</surname><given-names>GR</given-names></name></person-group><article-title>Inefficient growth arrest in response to dNTP starvation stimulates gene amplification through bridge-breakage-fusion cycles</article-title><source>Mol. Biol. Cell</source><year>1996</year><volume>7</volume><fpage>345</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">8868464</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paulson</surname><given-names>TG</given-names></name><name><surname>Almasan</surname><given-names>A</given-names></name><name><surname>Brody</surname><given-names>LL</given-names></name><name><surname>Wahl</surname><given-names>GM</given-names></name></person-group><article-title>Gene amplification in a p53-deficient cell line requires cell cycle progression under conditions that generate DNA breakage</article-title><source>Mol. Cell. Biol</source><year>1998</year><volume>18</volume><fpage>3089</fpage><lpage>3100</lpage><pub-id pub-id-type="pmid">9566927</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>MJ</given-names></name><name><surname>Mesner</surname><given-names>LD</given-names></name><name><surname>Friedman</surname><given-names>CL</given-names></name><name><surname>Trask</surname><given-names>BJ</given-names></name><name><surname>Hamlin</surname><given-names>JL</given-names></name></person-group><article-title>Amplification of the human dihydrofolate reductase gene via double minutes is initiated by chromosome breaks</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2000</year><volume>97</volume><fpage>7921</fpage><lpage>7926</lpage><pub-id pub-id-type="pmid">10859355</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>N</given-names></name><name><surname>Shingaki</surname><given-names>K</given-names></name><name><surname>Kaneko-Sasaguri</surname><given-names>Y</given-names></name><name><surname>Hashizume</surname><given-names>T</given-names></name><name><surname>Kanda</surname><given-names>T</given-names></name></person-group><article-title>When, where and how the bridge breaks: anaphase bridge breakage plays a crucial role in gene amplification and HSR generation</article-title><source>Exp. Cell Res</source><year>2005</year><volume>302</volume><fpage>233</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">15561104</pub-id></element-citation></ref></ref-list></back></article>
